• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    CMS Establishes New Payment for Pelvalon’s Eclipse System

    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy

    Resonetics Leases New Manufacturing Space in Costa Rica

    Seisa Medical Acquires ProtoQuick and Peridot

    Masimo Device is Useful in Assessing Respiratory Status of Pediatric Tracheostomy Patients
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Transporting Treatment: An Examination of Tubing Technologies

    Outward Appearance: Reviewing Surface Treatment Options

    Face to (Virtual) Face: Telemedicine Now and Post-Pandemic

    Voices for Medtech: AdvaMed and MDMA Leaders Share Thoughts

    Digitize Your QMS via an Enterprise Cloud Platform
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Home Is Where the Heart (Valve) Is

    CGM: Digital Health Meets a Very Large Opportunity

    Biomechanical Engineer, Heal Thyself

    Optimizing MIM in Medical Device Manufacturing

    PPE and Diagnostics: Sourcing Domestically and Speeding Time to Market
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    MW Life Sciences

    Qosina Corp.

    Trademark Plastics Inc.

    K-Tube Technologies

    Creganna Medical, part of TE Connectivity
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Three Future Trends and Opportunities in Quality Assurance

    Adopting a Data-Driven Quality Model

    Digital Transformation for Quality and Manufacturing

    Digging into the Cardiac Arrhythmia Monitoring Device Market

    EMS Providers Supplying More Than Electronics to Customers
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Spectrum Plastics Group

    PTI Engineered Plastics Inc.

    K-Tube Technologies

    Unicep

    Qosina Corp.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    Improved Outcomes Seen in More Complete Revascularization Using Impella Heart Pumps

    Impella use led to a 29 percent reduction in MACCE at 90 days.

    Business Wire11.30.20
    Abiomed announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and repeat procedures) when Impella heart pumps are used to achieve a more complete revascularization in a single setting for high-risk percutaneous coronary intervention (PCI) patients. PROTECT III is an ongoing, prospective, single-arm U.S. Food and Drug Administration (FDA) post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI. 
     
    PROTECT III builds on the PROTECT II Randomized Controlled Trial (RCT) which found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29 percent reduction in MACCE at 90 days. The study authors analyzed patients in PROTECT III who would have qualified for PROTECT II, known as “PII-like” patients, and compared them to PROTECT II patients. PII-like patients in PROTECT III had improved 90-day MACCE rates, compared to PROTECT II patients (15 percent vs. 21.9 percent, p=0.035). 
     
    The study also found PII-like patients in PROTECT III were older, sicker and more complex, with more comorbidities, more vessels treated and more rotational atherectomy, yet they had improved in-hospital safety with:
    • Significantly fewer bleeding complications (1.8 percent vs. 12.5 percent, p<0.001)
    • Similar low vascular complications (1 percent vs. 1.4 percent, p=0.659)
    • Similar low instances of stroke (0.40 percent vs. 0.46 percent, p=0.913)
     
    The PROTECT series of FDA clinical studies, which includes PROTECT I, the PROTECT II RCT and PROTECT III, is the largest-ever FDA study of hemodynamically supported high-risk PCI patients. This PROTECT III interim analysis included 1,143 patients undergoing elective non-emergent PCI with Impella at 45 sites between March 2017 and September 2019.
     
    “This data is an important continuation of knowledge in high-risk PCI. Looking back at PROTECT II data, we understood the safety and efficacy of Impella,” said Jeffrey W. Moses, M.D., a PROTECT III lead investigator and director of interventional cardiovascular therapeutics and professor of medicine at Columbia University Medical Center. “But now, with PROTECT III showing fewer adverse events, we understand how to apply best practices and the result is better patient outcomes.”
     
    “This novel, contemporary data from PROTECT III clearly demonstrates how the evolution and adoption of Impella best practices can lead to an improvement in safety and MACCE and it provides important information as we prepare for the upcoming PROTECT IV Randomized Controlled Trial of Impella in high-risk PCI,” said William O'Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital.
     
    PROTECT III is part of a growing body of evidence supporting the benefits of a more complete revascularization in high-risk PCI, which leads to better patient outcomes. The Restore EF study demonstrates the use of contemporary best practices with Impella in high-risk PCI significantly improves left ventricular ejection fraction (LVEF), heart failure symptoms, and anginal symptoms at 90-day follow up in a wide variety of hospitals settings including rural, urban, community and academic centers. PROTECT III also strengthens the overall body of evidence about Impella safety.
     
    The PROTECT III post-approval study will inform best practice protocols for the upcoming prospective, two-arm PROTECT IV RCT, which will leverage and validate key learnings from the cVAD Study, Impella Quality (IQ) Database and real-world data collected since the completion of the PROTECT II RCT. PROTECT IV will compare complete revascularization PCI with Impella to complete revascularization PCI without any planned hemodynamic support.
     
    The PROTECT series of studies are sponsored by Abiomed as part of its commitment to improving clinical outcomes.
     
    The Impella 2.5 and Impella CP devices are FDA PMA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to reopen blocked coronary arteries. The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD, and Impella 5.5 with SmartAssist are FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella RP is FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery. The Impella RP is also authorized for emergency use by healthcare providers (HCPs) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients with a body surface area ≥1.5 m2, for the treatment of acute right heart failure or decompensation caused by complications related to coronavirus disease 2019 (COVID‐19), including pulmonary embolism (PE). The Impella RP has not been cleared or approved for the treatment of acute right heart failure or decompensation caused by complications related to COVID-19. Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
     
    In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days. Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days. The Impella 5.5 with SmartAssist is CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 30 days. The Impella RP is CE marked to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery, or refractory ventricular arrhythmia. 
     
     
    Related Searches
    • Cardiovascular
    Related Knowledge Center
    • Cardiovascular

    Related Breaking News

    • Cardiovascular
      USPTO Issues Patent Covering Hancock Jaffe’s VenoValve

      USPTO Issues Patent Covering Hancock Jaffe’s VenoValve

      Valve is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency (CVI).
      Charles Sternberg, Assistant Editor 04.08.21

    • Cardiovascular | Surgical
      Abbott

      Abbott's Next-Gen TriClip Earns EU Nod

      New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve.
      Sam Brusco, Associate Editor 04.08.21

    • Cardiovascular | Patient Monitoring
      GE Healthcare Reveals Venue Fit POC Ultrasound with Cardiac AI Tool

      GE Healthcare Reveals Venue Fit POC Ultrasound with Cardiac AI Tool

      AI tool continuously calculates the heart’s real-time ejection fraction.
      Sam Brusco, Associate Editor 03.31.21


    • Cardiovascular
      Heart Failure Treatment Using Electrical Microcurrent Shows Promise

      Heart Failure Treatment Using Electrical Microcurrent Shows Promise

      Berlin Heals' C-MIC device restores endogenous electric potential gradients using microcurrents, leading to improved myocardial function.
      Michael Barbella, Managing Editor 03.30.21

    • Cardiovascular
      FDA Breakthrough Status Granted to Cook Medical

      FDA Breakthrough Status Granted to Cook Medical's Zenith Endovascular Graft

      ZFEN+ includes up to five precisely located fenestrations to accommodate the visceral vessels.
      Michael Barbella, Managing Editor 03.29.21

    • Cardiovascular
      FDA Approves Medtronic

      FDA Approves Medtronic's Harmony TPV for Congenital Heart Disease

      Less invasive option to treat pulmonary valve regurgitation for patients with a native or surgically-repaired right ventricular outflow tract.
      Sam Brusco, Associate Editor 03.26.21


    • Cardiovascular | Surgical
      CSI Buys Peripheral Support Catheters from WavePoint Medical

      CSI Buys Peripheral Support Catheters from WavePoint Medical

      Agreement also includes development of portfolio of chronic total occlusion products.
      Sam Brusco, Associate Editor 03.22.21

    • Cardiovascular
      Cardinal Health to Sell Cordis Biz to Hellman & Friedman for $1B

      Cardinal Health to Sell Cordis Biz to Hellman & Friedman for $1B

      Transaction is expected to close in the first half of Cardinal Health's fiscal year 2022.
      Sam Brusco, Associate Editor 03.12.21

    • Cardiovascular
      Global Cardiovascular Devices Market to Exceed $62 Billion by 2025

      Global Cardiovascular Devices Market to Exceed $62 Billion by 2025

      Sector to be driven in part by the robust performance of cardiac assist products.
      Michael Barbella, Managing Editor 03.12.21


    • Cardiovascular
      China to Lead APAC Interventional Cardiology Devices Market Through 2025

      China to Lead APAC Interventional Cardiology Devices Market Through 2025

      Cardiovascular diseases are the major cause of morbidity and mortality in the nation.
      Michael Barbella, Managing Editor 03.10.21

    • Cardiovascular
      Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib

      Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib

      Will evaluate PulseSelect's pulsed electrical fields to interrupt irregular heart rhythms.
      Sam Brusco, Associate Editor 03.04.21

    • Cardiovascular
      Soundbite Medical Wins Health Canada Approval for PAD Treatment

      Soundbite Medical Wins Health Canada Approval for PAD Treatment

      Product targets patients with heavily calcified chronic total occlusions.
      Michael Barbella, Managing Editor 03.02.21


    • Cardiovascular
      Novel Heart Failure Treatment Technology Scores Positive Trial Results

      Novel Heart Failure Treatment Technology Scores Positive Trial Results

      All patients treated with Vascular Dynamics' MobiusHD Device showed improvement.
      Michael Barbella, Managing Editor 03.01.21

    • Cardiovascular
      FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump

      FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump

      Puzzle Medical Device's ModulHeart helps patients avoid open-heart surgery and reduces blood trauma.
      Michael Barbella, Managing Editor 02.25.21

    • Cardiovascular
      NTT Research, Japanese Entity to Collaborate on Cardiovascular Disease Interventions

      NTT Research, Japanese Entity to Collaborate on Cardiovascular Disease Interventions

      NCVC in Japan will develop computational models while NTT Research MEI Lab will implement a bio digital twin platform.
      Michael Barbella, Managing Editor 02.24.21


    Trending
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Cheetah Medical Introduces Noninvasive Monitoring System
    • Face Mask Filters 98 Percent Of COVID-19 Particles
    • Diagnosing The IVD Market: An Interview With TEAM Technologies
    • Top 10 Trends In The Medical Device And Equipment Industry
    Breaking News
    • CMS Establishes New Payment for Pelvalon’s Eclipse System
    • Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    • Resonetics Leases New Manufacturing Space in Costa Rica
    • Seisa Medical Acquires ProtoQuick and Peridot
    • Masimo Device is Useful in Assessing Respiratory Status of Pediatric Tracheostomy Patients
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Transporting Treatment: An Examination of Tubing Technologies
    • Face to (Virtual) Face: Telemedicine Now and Post-Pandemic
    • Outward Appearance: Reviewing Surface Treatment Options
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    What You’re Reading on Happi.com
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login